Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nektar Therapeutics
Friedreich’s ataxia is particularly prevalent in Europe, and the company hopes to replicate the fast US uptake for Skyclarys there.
More than 75 industry executives and experts gazed into the crystal ball and shared with Scrip their predictions around transformative technologies. Perhaps unsurprisingly, AI was the dominant theme – but gene editing, cell therapies and new targeting modalities were also among the highlights.
A draft bill from the US House related to national security issues sent WuXi Biologics' shares tumbling over concerns around increased US scrutiny of Chinese firms, which a company clarification did little to dispel.
In Swift Challenge To Orange Book Patent Listings, Federal Trade Commission Fills FDA Ministerial Gap
Agency sends letters to 10 companies saying they improperly listed patents in US FDA’s Orange Book covering drug-device combination products. FTC does not specify why it believes the patents were improperly listed.
- Drug Delivery
- Drug Discovery Tools
- Large Molecule
- Other Names / Subsidiaries
- Aerogen, Inc.
- Inhale Therapeutic Systems, Inc.
- Inheris Biopharma, Inc.
- Nektar Therapeutics (India) Private Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.